🔬🧬 Oncology Updates: Keytruda Trials, Tumor-Agnostic Therapies, and Global Cancer Drug Approvals
From Japan’s approval of immunotherapy combos to China’s first solid tumor CAR-T NDA and breakthrough pancreatic cancer designations—this week’s oncology roundup highlights global milestones reshaping cancer care and precision medicine.
💡 Key Highlights This Week:
✅ TuHURA initiates Phase 3 trial of IFx-2.0 + Keytruda in Merkel Cell Carcinoma; triggers $2.23M from PIPE financing
✅ Datroway approved by FDA for EGFR-mutant NSCLC post-therapy, showing 45% ORR and 6.5-month DoR
🧬 Hetronifly (Serplulimab) becomes the first anti-PD-1 approved in the UK for extensive-stage small cell lung cancer with 4-year OS of 21.9%
🧪 BriaCell’s breast cancer trial receives 3rd positive DSMB review; Bria-IMT + checkpoint inhibitor studied under Fast Track
🇨🇳 CARsgen’s Satri-cel becomes the first CAR-T for solid tumors to reach NDA stage in China targeting Claudin18.2-positive gastric cancers
🚀 Revolution Medicines gains FDA Breakthrough Therapy Designation for KRAS G12-mutant pancreatic cancer therapy daraxonrasib
🇯🇵 Opdivo + Yervoy combo approved in Japan for unresectable hepatocellular carcinoma with median OS of 23.7 months
🧫 Bio-Thera’s BAT8006 enters Phase 3 trial for platinum-resistant ovarian cancer with 40.7% ORR and no ocular toxicity
🤝 Gilead and Kymera sign $750M CDK2 degrader partnership for cancers driven by CDK2; $85M upfront
🧬 Chugai files Alecensa for tumor-agnostic ALK+ solid tumors in Japan, showing 76.5% ORR in Phase II
🎯 Corbus begins CRB-701 + Keytruda Phase 1 trial for high Nectin-4-expressing tumors; 100+ patients already dosed with monotherapy
🎯 Whether you’re tracking tumor-agnostic approaches, next-gen immunotherapies, or oncology deal-making—this episode delivers the must-know developments driving cancer innovation worldwide.
📢 Stay Ahead in Oncology Research!
✅ Like, share, and subscribe for weekly updates on oncology breakthroughs and cancer immunotherapy
#Oncology #CancerResearch #Immunotherapy #ClinicalTrials #Keytruda #EGFR #KRAS #CDK2 #CAR_T #MerkelCellCarcinoma #PancreaticCancer #LungCancer #HepatocellularCarcinoma #BreastCancer #OvarianCancer #ALK #LucidQuest #BiotechNews #PharmaInnovation #SolidTumors #HealthcareUpdates